Sevval Nur Bilgic

5PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 06, 2025
Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2-Mutant Cholangiocarcinoma.

Eylül Özgü, Ünal Metin Tokat, Ashkan Adibi

|Nov 14, 2024
Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety.

Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın

|Oct 25, 2024
Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers.

Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın

|May 10, 2023
EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.

Sevval Nur Bilgic, Aylin Domaniku, Batu Toledo

|Apr 04, 2022
Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia.

Bahar Zehra Camurdanoglu Weber, Samet Agca, Aylin Domaniku

Pageof 1

Frequent Collaborators

3 joint publications

Esranur Aydın

3 joint publications

Mutlu Demiray

2 joint publications

Samet Agca

2 joint publications

Aylin Domaniku